Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven primary IgA nephropathy with urinary proteinuria excretion over 1g/24 hour,subjects must meet 2 of the following criteria:~  1. global glomerular sclerosis plus focal segmental glomerular sclerosis ratio ≥50%~ 2. eGFR 30 to 60 ml/min~ 3. Hypertension (blood pressure over 140/90 mmHg or taking antihypertensive drugs)~Exclusion Criteria:~1. Secondary IgA nephropathy~2. Familial IgA nephropathy~3. Concomitant disease: cancer, infection, diabetes mellitus, connective tissue disease, abnormal liver function~4. Pregnancy or breasting~5. Inability to comply with study and follow-up procedures

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- mycophenolate mofetil (Type: EXPERIMENTAL): mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
- losartan (Type: ACTIVE_COMPARATOR): maximus tolerated labeled dose of losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).